Baltimore, USA - 01 Sep `17Early Molecular Changes After NB-UVB

Official Title: Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

In Brief: This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with vitiligo and normal skin in healthy participants. Participants diagnosed with vitiligo who are enrolled in the study will receive phototherapy (NB-UVB), with the starting dose of 250 mJ/cm2. The dose will be increased by 10% with each treatment. Small skin samples will be collected before and after NB-UVB treatment.

Ages Eligible: 18 Years to 100 Years

Start Date: September 1, 2017 

Completion Date (estimated): September 1, 2022

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03270241

Location: Johns Hopkins Outpatient Center, Baltimore, Maryland, United States, 21287

Contact: To learn more about this study, you or your doctor may contact Ruizhi Wang by phone +1-410-502-7546 or email CTReP@jhmi.edu. Please refer to this study by its NCT number.

FAQOther Questions

  • Will it spread?

    Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

  • I have vitiligo: will my children have vitiligo, too?

    Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...